Stock Events

Stock Events

Viatris 

$19.91
1617
+$0.94+4.96%Friday 21:00
+$0.04+0.2%Saturday 00:38After hours

Statistics

Day High
19.94
Day Low
18.8
52W High
19.96
52W Low
9.92
Volume
14,437,429
Avg. Volume
8,883,826
Mkt Cap
22.87B
P/E Ratio
-
Dividend Yield
2.41%
Dividend
0.48

Upcoming

Dividends

2.41%Dividend Yield
Sep 2026
$0.12
Jun 2026
$0.12
Mar 2026
$0.12
Dec 2025
$0.12
Sep 2025
$0.12
10Y Growth
N/A
5Y Growth
16.89%
3Y Growth
N/A
1Y Growth
N/A

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Q3 2026
0.49
0.56
0.64
0.71
Expected EPS
0.636689
Actual EPS
0.71

Financials

-24.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
14.3BRevenue
-3.51BNet Income

Analyst Ratings

$21.00Average Price Target
The highest estimate is ⁦26.00⁩.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
71%
Hold
29%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VTRS. It's not an investment recommendation.
Pfizer
405
PFE
AT&T
330
T
Realty Income
305
O
Apple
285
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries is a direct competitor, focusing on generic and specialty medicines, similar to Viatris' product offerings.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, originally part of Viatris through Upjohn, competes in the pharmaceuticals space, offering both branded and generic drugs.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes with Viatris in the specialty pharmaceutical sector, particularly in areas like biosimilars and branded generics.
Novartis
NVS
Mkt Cap303.67B
Novartis, through its Sandoz division, is a major player in the generic drugs market, making it a direct competitor to Viatris.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson competes across a broad range of healthcare products, including pharmaceuticals that overlap with Viatris' market.
Merck
MRK
Mkt Cap368.89B
Merck & Co. competes with Viatris in the pharmaceutical sector, particularly in the development and marketing of prescription medicines.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes in the pharmaceutical and healthcare sector, with a portfolio that includes prescription medicines and vaccines.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes with Viatris in the biopharmaceutical sector, particularly in the development of biosimilars and novel therapeutics.
Sanofi
SNY
Mkt Cap106.24B
Sanofi competes in the global pharmaceutical market, offering a broad portfolio of prescription drugs that overlaps with Viatris' offerings.

About

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Show More
CEO
Scott Andrew Smith
Employees
30000
Country
United States
ISIN
US92556V1061
WKN
000A2QAME

Listings

LSE
GB
0A5V.LSE
STU
DE
VIA.STU
XNAS
US
VTRS
MU
DE
VIA.MU

0 Comments

Share your thoughts

FAQs

What is Viatris stock price today?▼
The current price of VTRS is $19.91 USD — it has increased by +4.96% in the past 24 hours. Watch Viatris stock price performance more closely on the chart.
What is Viatris stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Viatris stocks are traded under the ticker VTRS.
Is Viatris stock price growing?▼
VTRS stock has risen by +4.6% compared to the previous week, the month change is a +14.16% rise, over the last year Viatris has showed a +96.74% increase.
What is Viatris market cap?▼
Today Viatris has the market capitalization of 22.87B
When is the next Viatris earnings date?▼
Viatris is going to release the next earnings report on March 1, 2027.
What were Viatris earnings last quarter?▼
VTRS earnings for the last quarter are 0.71 USD per share, whereas the estimation was 0.64 USD resulting in a +11.51% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Viatris revenue for the last year?▼
Viatris revenue for the last year amounts to 14.3B USD.
What is Viatris net income for the last year?▼
VTRS net income for the last year is -3.51B USD.
Does Viatris pay dividends?▼
Yes, VTRS dividends are paid quarterly. The last dividend per share was 0.12 . As of today, Dividend Yield (FWD)% is 2.41%.
How many employees does Viatris have?▼
As of November 8, 2026, the company has 30,000 employees.
In which sector is Viatris located?▼
Viatris operates in the Health & Wellness sector.
When did Viatris complete a stock split?▼
Viatris has not had any recent stock splits.
Where is Viatris headquartered?▼
Viatris is headquartered in CANONSBURG, United States.